Differentiation of astrocytoma between grades II and III using a combination of methionine positron emission tomography and magnetic resonance spectroscopy

• Published in: World neurosurgery: X Vol. 19; p. 100193
• Main Authors: Yano, Hirohito, Miwa, Kazuhiro, Nakayama, Noriyuki, Maruyama, Takashi, Ohe, Naoyuki, Ikuta, Soko, Ikegame, Yuka, Yamada, Tetsuya, Takei, Hiroaki, Owashi, Etsuko, Ohmura, Kazufumi, Yokoyama, Kazutoshi, Kumagai, Morio, Muragaki, Yoshihiro, Iwama, Toru, Shinoda, Jun
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-07-2023; Elsevier
• Subjects: Glioma; Grading; Isocitrate dehydrogenase; Magnetic resonance spectroscopy; Methionine; Original; Positron emission tomography; MRI; Cho; IDH; CDM; AUC; Cr; MRS; Magnetic resonance spectroscopy; T/N; WI; NPV; PPV; Grading; Isocitrate dehydrogenase; Methionine; ROC; HGG; FOV; LGG; ROI; NAA; TE; A-II; Glioma; A-III; SUV; TI; Positron emission tomography; Gd; MET; PET; TR
• ISSN: 2590-1397; 2590-1397
• DOI: 10.1016/j.wnsx.2023.100193

This study aimed to establish a method for differentiating between grades II and III astrocytomas using preoperative imaging.
We retrospectively analyzed astrocytic tumors, including 18 grade II astrocytomas (isocitrate dehydrogenase (IDH)-mutant: IDH-wildtype = 8:10) and 56 grade III anaplastic astrocytomas (37:19). We recorded the maximum methionine (MET) uptake ratios (tumor-to-normal: T/N) on positron emission tomography (PET) and three MRS peak ratios: choline (Cho)/creatine (Cr), N-acetyl aspartate (NAA)/Cr, and Cho/NAA, between June 2015 and June 2020. We then evaluated the cut-off values to differentiate between grades II and III. We compared the grading results between contrast enhancement effects on MR and combinational diagnostic methods (CDM) on a scatter chart using the cutoff values of the T/N ratio and MRS parameters.
The IDH-mutant group showed significant differences in the Cho/NAA ratio between grades II and III using univariate analysis; however, multiple regression analysis results negated this. The IDH-wildtype group showed no significant differences between the groups. Contrast enhancement effects also showed no significant differences in IDH status. Accordingly, regardless of the IDH status, no statistically independent factors differentiated between grades II and III. However, CDMs showed higher sensitivity and negative predictive value in distinguishing them than MRI contrast examinations for both IDH statuses. We demonstrated a significantly higher diagnostic rate of grade III than of grade II with CDM, which was more striking in the IDH-mutant group than in the wild-type group.
CDM could be valuable in differentiating between grade II and III astrocytic tumors.